Analyst Price Targets — KALV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 1, 2026 10:05 am | Andrew Fein | H.C. Wainwright | $27.00 | $26.66 | TheFly | KalVista downgraded to Neutral from Buy at H.C. Wainwright |
| April 29, 2026 10:26 pm | — | Leerink Partners | $27.00 | $26.67 | TheFly | KalVista downgraded to Market Perform from Outperform at Leerink |
| January 9, 2026 11:09 am | Andrew Fein | H.C. Wainwright | $37.00 | $15.82 | TheFly | KalVista price target raised to $37 from $27 at H.C. Wainwright |
| January 6, 2026 12:42 pm | — | Needham | $32.00 | $15.66 | TheFly | KalVista price target raised to $32 from $28 at Needham |
| November 11, 2025 10:50 am | — | JMP Securities | $28.00 | $10.89 | TheFly | KalVista price target lowered to $28 from $29 at Citizens JMP |
| November 5, 2024 12:09 pm | Serge Belanger | Needham | $28.00 | $11.25 | StreetInsider | Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $28 at Needham |
| September 6, 2024 6:54 am | Andrew Fein | H.C. Wainwright | $20.00 | $12.87 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV) |
| September 6, 2024 6:35 am | Joseph Schwartz | Leerink Partners | $20.00 | $12.87 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Kalvista Pharmaceuticals Inc (KALV) |
| July 8, 2022 4:29 am | — | Needham | $38.00 | $10.98 | Benzinga | Needham Maintains Buy on KalVista Pharmaceuticals, Lowers Price Target to $38 |
No recent news available for KALV.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KALV.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.